| 
Results for keryx biopharmaceuticals. Search took 0.31 seconds.
Roche Invests $387 million in Biotech Drug Research
in The Biotech Weblog, on January 28, 2008
...39;s own value added chain is exploited to its full potential in the development and production of biopharmaceuticals mainly for oncology applications .
Source: Roche ...
Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
in Supplychainer, on September 7, 2007
... is its support of variable dosing (variable titration) trials, which are in increasing use by many biopharmaceuticals. tcVisualize 3.0 is the only tool that can model and compare scenarios around the...
Evithrom (human thrombin) FDA-approved for Topical Use in Surgery
in Straightfromthedoc, on August 29, 2007
... Evithrom (human thrombin) - manufactured by Omrix Biopharmaceuticals, Ltd. and will be distributed by Johnson & Johnson Wound Management (a division of Ethicon, Inc.) - is the first human th...
Transgenic Mushrooms as Drug Biofactories
in The Biotech Weblog, on June 25, 2007
...on of commercially valuable proteins. Mushrooms could make the ideal vehicle for the manufacture of biopharmaceuticals to treat a broad array of human illnesses. But nobody has been able to come up wi...
Morgan Stanley Expect Favorable Returns from Large Biotech Companies
in The Biotech Weblog, on July 20, 2006
...Morgan Stanley analyst.
Among Morgan Stanley's top picks were:
MedImmune : Products include biopharmaceuticals for infectious diseases, oncology and immunology : Flumist® , Synagis® , ...
Cardeva™ for Chronic Heart Failure (CHF), Clinical Trial On-going
in Straightfromthedoc, on July 20, 2006
...n protein) the most advanced compound in CoGenesys' broad pipeline of improved, long-acting biopharmaceuticals being developed to address unmet medical needs across a broad spectrum of therapeutic...
Plant-derived Vaccine by Fusion Molecules
in The Biotech Weblog, on March 14, 2006
...o produce vaccines against HIV and other diseases. This could be the start of cheaper and effective biopharmaceuticals.
Source: [ EurekAlert ]
...
NicVax on Fast Track Status
in The Biotech Weblog, on March 13, 2006
... 2005, the smoking vaccine showed favorable clinical trial results . This week, manufacturer Nabi Biopharmaceuticals said that it has received fast-track status for NicVAX for nicotine addiction...
3rd Annual Florida Tech Transfer Conference
in The Biotech Weblog, on February 1, 2006
...s available for commercialization and licensing in the following categories:
Pharmaceuticals and Biopharmaceuticals
Engineering and Materials Sciences
Medical Devices and Other Biotechnologies ...
Top Five Regions For Biotech Companies
in The Biotech Weblog, on January 26, 2006
...s become a hot property in the biotech world, drawing in a big vaccine plants from BioPort and Nabi Biopharmaceuticals as well.
New Jersey
It's added $50,000 bridge grants to help a bi...
Warburg & CITIC Funds China Pharmaceuticals
in China Venture News, on November 9, 2005
... high price tag for consumers but are relatively cheap to produce.
The company also specializes in biopharmaceuticals, or medicines that use biological agents such as recombinant DNA in the manufactu...
Novartis Takes Over Chiron Corp
in The Biotech Weblog, on November 7, 2005
...s?
Chiron operates three business segments: the fast-growing vaccines division, blood testing and BioPharmaceuticals, which makes drugs for infectious diseases and cancer. The biopharmaceutic...
21 companies to watch
in TJ's Weblog, on October 19, 2004
Red Herring selects 21 companies that have a good chance to make it big. Good summaries...
The Business of the Future
in Businesspundit, on May 9, 2003
...0 years. I like cryptography, nanotechnology, quantum computing, artificial intelligence and biopharmaceuticals, but I think the most life changing technologies of the future will spring from n...
Keryx Biopharmaceuticals' Common Stock Offering
in The Biotech Weblog, on July 18, 2005
...
Keryx Biopharmaceuticals, Inc. announced yesterday the pricing of its public offering of 5,030,000 shares of its common stock at an offering price of $14.05 per share. J.P. Morgan Securities I... ...
Keryx Biopharmaceuticals, Inc. announced yesterday the pricing of its public offering of 5,030,000 shares of its common stock at an offering price of $14.05 per share. J.P. Morgan Securities I...